Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TAK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tak · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Takeda Pharmaceutical Company Limited (TAK) measures how much investors pay for each dollar of the company's trailing earnings. TAK's current PE ratio of 41.15x is calculated by dividing its stock price of $15.77 by its TTM earnings per share of $122.72. +1.9% elevated vs 5Y avg 40.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%23.7x
MedianQ3 · 75%114.9x
Max
At 41.15x, TAK's current P/E is within its average historical range over the past 19 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Takeda Pharmaceutical Company LimitedYou TAK | $49.8B | 41.15x | +30.1% | $122.72 |
 Agilent Technologies, Inc. A | $37.7B | 31.79x | +0.5% | $4.60 |
 Alcon Inc. ALC | $32.4B | 39.80x | +25.9% | $1.98 |
 Becton, Dickinson and Company BDX | $54.6B | 25.13x | -20.5% | $5.85 |
 Cardinal Health, Inc. CAH | $48.1B | 25.94x | -18.0% | $6.48 |
 Edwards Lifesciences Corporation EW | $49.6B | 46.44x | +46.9% | $1.84 |
 Haleon plc HLN | $39.6B | 20.62x | -34.8% | $0.36 |
Industry Average 6 peers with valid PE | — | 31.62x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 45.54x | $64.55 | -31.3% | |
2025-03-31 FY2025 | 66.33x | $33.61 | +47.3% | |
2024-03-31 FY2024 | 45.02x | $46.04 | +110.2% | |
2023-03-31 FY2023 | 21.41x | $102.14 | -9.6% | |
2022-03-31 FY2022 | 23.68x | $73.57 | +41.0% | |
2021-03-31 FY2021 | 16.79x | $120.36 | -85.4% | |
2020-03-31 FY2020 | 114.87x | $14.21 | +185.7% | |
2019-03-31 FY2019 | 40.20x | $56.75 | +85.5% | |
2018-03-31 FY2018 | 21.67x | $119.67 | -39.4% | |
2017-03-31 FY2017 | 35.78x | $73.58 | -28.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Takeda Pharmaceutical Company Limited (TAK) measures how much investors pay for each dollar of the company's trailing earnings. TAK's current PE ratio of 41.15x is calculated by dividing its stock price of $15.77 by its TTM earnings per share of $122.72.
Frequently asked questions
TAK pe ratio · 6 questionsTAK's current PE ratio is 41.15x as of 2026-06-08, based on a stock price of $15.77 and TTM EPS of $122.72. Data sourced from Financial Modeling Prep via TAK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Takeda Pharmaceutical Company Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08